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1. Introduction
Alzheimer’s disease (AD) is  a neurodegenerative disorder of the central  nervous system
characterized by a progressive loss of short-term memory accompanied by a gradual loss
of cognitive functions (Ross et  al.,  2004).  AD is among the most frequently encountered
diseases in aging societies with an estimated 5million people in the United States and 17
million people  worldwide suffering from the  disease.  It  is  expected that  these  numbers
will quadruple by the year 2040, by which 1 out of 45 Americans will be affected, leading
to  a  considerable  public  health  burden  (Fratiglioni  et  al.,  1999).  AD pathogenic  mecha‐
nisms  contributing  to  neuronal  loss  and  brain  dysfunction  are  still  unclear.  However,
remarkable  advances  have  taken  place  in  understanding  of  both  the  genetics  and
molecular  biological  aspects  of  the  intracellular  processing  of  amyloid  and tau  and the
changes  leading  to  the  pathologic  formation  of  extracellular  amyloid  plaques  and  the
intraneuronal  aggregation  of  hyperphosphorylated  tau  into  neurofibrillary  tangles.  This
progress in our understanding of  the molecular pathology has set  the stage for clinical‐
ly meaningful advances in the development of biomarkers.
Proper  diagnosis  is  essential  for  instituting  appropriate  clinical  management.  While
diagnostic accuracy for the disease has improved, the differential diagnosis of the disorder
is  still  problematic.  In the very early stages of  the disease,  frequently classified as  mild
cognitive  impairment  (MCI),  delineating  disease  process  from “normal  ageing”  may  be
difficult; in later stages of the disease, distinguishing AD from a number of neurodegener‐
ative  diseases  associated  with  dementia  may  also  be  difficult.  Furthermore,  the  disease
progression is slow and there is variability of performance on clinical measures, making
it  difficult  to monitor change effectively.  Since disease modifying therapy is likely to be
most  effective  early  in  the  course  of  disease,  early  diagnosis  is  highly  desirable  before
neurodegeneration becomes severe and widespread.
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In  clinical  practice,  the  diagnosis  of  AD  is  still  largely  based  on  consensuscriteria
combined with the exclusion of secondary causes of memory loss (Knopman et al.,  2001;
McKhann et  al.,  1984).Thus,  there is  an urgent and desperate need for a biomarker that
can reliably prognose the disease. Biomarkers of AD occupy an essential place in recently
formulated diagnostic criteria for AD, in which their role is to identify the pathophysio‐
logical processes underlying cognitive impairment or to help predict time to reach up to
dementia.  Criteria  for  a  useful  biomarker  have  been  proposed  by  an  international
consensus group on molecular and biochemical markers of AD in 1998 (The Ronald and
Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute
on  Aging  Working  Group,  1998).  According  to  these  guidelines,  a  biomarker  for  AD
should  detect  a  manifestation  of  the  fundamental  neuropathology  and  be  validated  in
neuropathologically-confirmed cases.  Its  sensitivity for  detecting AD should exceed 80%
and its  specificity  in  differentiating between AD and other  dementias  should be  higher
than 80%. Ideally, a biomarker should also be reliable, reproducible, non-invasive, simple
to  perform,  and  inexpensive.  One  further  role  of  particular  interest  to  patients  and
clinicians dealing with AD is its ability to detect the disease at the earliest possible stage.
Based on growing body of evidence concerning the pathophysiology of AD, a number of
putative biological markers of disease have been evaluated against clinical and neuropa‐
thological  standards.  Biomarkers  are  very useful  for  diagnosing and monitoring disease
progression (Ward et  al.,  2007) and are important for patient selection,  monitoring side-
effects,  aiding selection of  appropriate  patient  treatment,  and helping new drug discov‐
ery. For the clinical studies of AD therapeutics, there is an increasing need for diagnostic
markers  to  ensure that  therapies  are  targeted at  the  right  patient  population,  to  initiate
early treatment when disease-modifying drugs will  be available,  and to monitor disease
progression (Hye et al.,  2006).
2. Biomarkers in CSF
One  of  the  most  promising  sources  of  biomarkers  in  AD  is  the  cerebrospinal  fluid
(CSF).The molecular  changes  in  the  brain  extracellular  and interstitial  environments  are
reflected in CSF. The single-cell layer epithelium separating the two compartments allows
a virtually unhindered flow of molecules from the brain towards the CSF. CSF biomark‐
ers for AD should reflect the central pathogenic processes in the brain. Furthermore the
CSF is accessible to trained clinicians using a relatively simple lumbar puncture (Fenton
et  al.,  1994).  Several  studies  have  investigated CSF inflammatory  markers,  immunologi‐
cal mediators, neurotrophins, metalloproteinases or isoprostenes. Candidate CSF biomark‐
ers  include  total  tau  (T-tau)  as  a  marker  for  the  neuronal  degeneration  (table  1),
phosphorylated  tau  (P-tau)  as  a  marker  for  tau  hyperphosphorylation  (table  2)  and
formation of tangles Aβ42 as a marker for Aβ  metabolism and plaque formation (table 3,
Blennow et al.,2003).
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Category Reference Sensitivity range
(100%) for AD
versus controls
Methods Study Title Study population
Tau Arai et al.,
1995
80-90 ELISA Tau in cerebrospinal fluid: a potential
diagnostic marker in Alzheimer's
disease
AD (n=70), non-AD (n=96)
control (n=19)
Tau Riemenschnei
der et al.,
1996
90-100 ELISA Cerebrospinal protein tau is elevated in
early Alzheimer’s disease.
AD(n=22), dementia(n=3)
Healthy controls(HC)(n=19)
Tau Shoiji et al.,
1998
20-30 ELISA Combination assay of CSF tau, A beta
1-40 and A beta 1-42(43) as a
biochemical marker of Alzheimer’s
disease
sporadic AD(n=55),
controls(n=34), non-AD
dementia(n=23), other
neurological diseases(n=45)
Tau Kanai et al.,
1998
30-40 ELISA Longitudinal study of cerebrospinal
fluid levels of tau, A beta1-40, and A
beta1-42(43) in Alzheimer’s disease: a
study in Japan
AD(n=93), non-AD
dementia(n=33) other
neurological diseases
(n=56), HC(n=54)
Tau Tapiola et al.,
1998
50-60 ELISA CSF tau is related to apolipoprotein E
genotype in early Alzheimer’s disease.
Early AD(n=81), other
dementia (n=43), non
demented neurologic
HC(n=33)
Tau Kahle et al.,
2000
50-60 ELISA Combined assessment of tau and
neuronal thread protein in Alzheimer’s
disease CSF
Probable AD(n=25), definite
AD(n=5), non demented
with PD (n=29), HC(n=16).
Tau Sjögren et al.,
2000
60-70 ELISA Decreased CSF -amyloid42 in
Alzheimer’s disease and amyotrophic
lateral sclerosis may reflect
mismetabolism of -amyloid induced by
separate mechanisms
AD (n = 19), FTD (n = 14),
ALS (n = 11) PD( n = 15)
HC(n = 17)
Tau Shoji et al.,
2002
50-60 ELISA Cerebrospinal fluid tau in dementia
disorders:a large scale multicenter study
by a Japanese study group
AD(n=366), 168 non-AD
dementia(n=168)
HC(n=181).
Tau Buerger et al.,
2002
70-80 ELISA Differential diagnosis of Alzheimer’s
disease with cerebrospinal fluid levels of
tau protein phosphorylated at
threonine 231
AD(n=82) FTD(n=26)
VD(n=20) HC(n=21)
Tau Riemenschnei
der et al.,
2002
80-90 ELISA Tau and Abeta42 protein in CSF of
patients with frontotemporal
degeneration
FTD(n=34), AD(n=74),
HC(n=40).
Tau Schönknecht
et al., 2003
50-60 ELISA Levels of total tau and tau protein
phosphorylated at threonine 181 in
patients with incipient and manifest
Alzheimer’s disease
manifest AD (n=43)
Incipient AD(n=8) VD(n=16)
HC(n=16)
Data from Blennow K, Hampel H (2003)
Table 1. CSF total tau (T-tau) as a diagnostic marker for AD
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Catagory Reference Sensitivity
(100%) for
AD versus
controls
Methods Study Title Study population
p- tau Ishiguro etal.,
1999
80-90 ELISA Phosphorylated tau in human cerebrospinal
fluid is a diagnostic marker for Alzheimer’s
disease.
AD (n=36) , Controls
(n=30)
p- tau Kohnken et al.,
2000
80-90 ELISA Detection of tau phosphorylated at
threonine 231 in cerebrospinal fluid of
Alzheimer’s disease patients
AD(n=27), non-
AD(n=31)
p- tau Sjögren et al.,
2001
40-50 ELISA The cerebrospinal fluid levels of tau, growth-
associated protein-43 and soluble amyloid
precursor protein correlate in Alzheimer’s
disease, reflecting a common
pathophysiological process
FTD( n = 14), AD( n =
47) VAD( n = 16),
controls (n = 12)
p- tau Itoh et al.,2001 90-100 ELISA Large-scale, multicenter study of
cerebrospinal fluid tau protein
phosphorylated at serine 199 for the
antemortem diagnosis of AD
AD( n = 236), non-AD
(n = 239), controls (n =
95)
p- tau Parnetti et al.,
2001
80-90 ELISA CSF phosphorylated tau is a possible marker
for discriminating AD from dementiawith
Lewy bodies. Phospho-Tau International
Study Group
AD (n=80), DLB (n=43)
Controls (n=40)
p-tau Sjögren et al.,
2002
50-60 ELISA Decreased CSF -amyloid42 in Alzheimer’s
disease and amyotrophic lateral sclerosis
may reflect mismetabolism of -amyloid
induced by separate mechanisms.
AD (n = 19), FTD (n =
14), ALS (n = 11) PD( n
= 15)
p- tau Buerger et al.,
2002
90-100 ELISA CSF tau protein phosphorylated at threonine
231 correlates with cognitive decline in MCI
subjects
MCI(n=77), probable
AD (n=55) Control
(n=30)
p-tau Hu et al., 2002 90-100 ELISA Levels of nonphosphorylated and
phosphorylated tau in cerebrospinal fluid of
Alzheimer’s disease patients: an
ultrasensitive bienzyme-substrate-recycle
enzyme-linked immunosorbent assay.
AD (n = 30), VaD, (n =
18) non-AD (n = 13):
depression (n = 3),
malignant lymphoma
(n = 2) control (n = 24)
p-tau Schönknecht et
al.,2003
60-70 ELISA CSF phosphorylated tau is a possible marker
for discriminating Alzheimer’s disease from
dementia with Lewy bodies. Phospho-Tau
International Study Group
AD (n=80) DLB (n=43)
Controls (n=40).
Data from Blennow K, Hampel H.(2003)
Table 2. CSF Phosphorylaterd tau (p-tau) as a diagnostic marker for AD
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Catagory Reference Sensitivity
(100%) for
AD versus
controls
Methods Study Title Study group
Aβ1-42 Galasko et al .,
1998
70-80 ELISA High cerebrospinal fluid tau and low amyloid beta42
levels in the clinical diagnosis of Alzheimer disease
and relation to apolipoprotein E genotype
Probable
AD(n=82), control
(n=60) ND (n= 74)
Aβ1-42 Andreasen et
al., 1999
90-100 ELISA Cerebrospinal fluid -amyloid(1-42) in Alzheimer’s
disease: differences between early- and late-onset
Alzheimer disease and stability during the course of
disease
AD (n=53)
Control (n=21)
Aβ1-42 Andreasen et
al.,1999
90-100 ELISA Sensitivity, specificity and stability of CSF t-tau in AD
in a community-based patient sample.
AD (n= 407)
Depression(n=28)
control (n=65).
Aβ1-42 Andreasen et
al., 1999C
80-90 ELISA Cerebrospinal fluid -amyloid(1-42) in Alzheimer’s
disease: differences between early- and late-onset
Alzheimer disease and stability during the course of
disease.
AD (n=53)
Control (n= 21)
Aβ1-42 Hulstaert et al.,
1999
70-80 ELISA Improved discrimination of AD patients using beta-
amyloid(1-42) and tau levels in CSF.
AD (n=150)
control (n= 100)
ND (n=84),
Aβ1-42 Otto et al.,
2000
90-100 ELISA Decreased beta-amyloid1-42 in cerebrospinal fluid
of patients with Creutzfeldt-Jakob disease
CJD (n=27),
AD(n=14), other
dementia(n=19),
NDC(n=20)
Aβ1-42 Kapaki et al.,
2001
70-80 ELISA Highly increased CSF tau protein and decreased
beta-amyloid (1-42) in sporadic CJD: a discrimination
from Alzheimer’s disease?
CJD (n=14),
AD(n=38)controls
(n=47).
Aβ1-42 Sjögren et al.,
2002
90-100 ELISA Decreased CSF -amyloid42 in Alzheimer’s disease
and amyotrophic lateral sclerosis may reflect
mismetabolism of -amyloid induced by separate
mechanisms
AD (n = 19), FTD
(n = 14), ALS (n =
11) PD ( n = 15)
controls (n = 17).
Data from Blennow K, Hampel H.(2003)
Table 3. CSF Aβ1-42as a diagnostic marker for AD
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2.1. Tau protein
One of the major neuropathological hallmarks of AD are neurofibrillary tangles composed of
paired helical filaments (PHF). The principal protein subunit of PHF is abnormally phos‐
phorylated tau (p-tau) (Iqbal et al., 1998). Physiologically, tau protein is located in neuronal
axons, in components of the cytoskeleton and in the intracellular transport systems. Total-tau
(t-tau) and truncated forms of monomeric and p-tau can be traced in the CSF. Using antibodies
that detect all isoforms of tau proteins independent of phosphorylation, or specific phosphor‐
ylation Core biomarker candidates of Alzheimer’s disease 251 sites, ELISA have been devel‐
oped to measure t-tau and p-tau concentrations (Vandermeeren et al., 1993; Blennow et al.,
2002, 1995; Hampel et al., 2003). CSF total tau protein in the differentiation between AD and
normal aging. Total tau protein, thought to be a general marker of neuronal destruction, has
been intensely studied in more than 2200 AD patients and 1000 age-matched elderly controls
over the last 10 years (Sunderland et al., 2003, table 1). The most consistent finding is a
statistically significant increase of CSF t-tau protein in AD. The mean level of CSF t-tau protein
concentration is about 3 times higher in AD compared to elderly controls. A sensitivity and
specificity level varies between studies primarily due to the different control groups used.
Specificity levels between 65% and 86% and sensitivity levels between 40% and 86% have been
found (Blennow et al., 2001, table 1). In several studies, a significant elevation was also found
in patients with early dementia (Galasko et al., 1997; Kurz et al., 1998; Riemenschneider et al.,
1997). In these studies of early dementia, the potential of CSF t-tau protein to discriminate
between AD and normal aging appeared high, with average 75% sensitivity and 85% specif‐
icity. An age-associated increase of t-tau protein has been shown in nondemented subjects
(Buerger et al., 2003; Sjogren et al., 2001b). Therefore, the effect of age should be considered
when t-tau protein levels are employed diagnostically.
2.2. Phosphorylated tau (p-tau)
Tau protein exists in six isoforms of 352–441 amino acids in length that are subject to a variety
of posttranslational modifications (Hanger et al., 2007) and, presumably, function. Of the 79
serine and threonine phosphorylation sites on the longest isoform of tau, 4R/2N, approxi‐
mately 40 have been verified (Iqbal et al., 2010) of which 25 have been identified as sites of
‘‘abnormal phosphorylation’’ (Mazanetz et al., 2007). The phosphorylation state of tau is the
net result of a balance of kinase and phosphatase activity. Much of the activity in tau-based
drug discovery has been focused on selective finding inhibitors of ‘‘tau kinase’’, a combination
of the activity of two serine/theronine kinases that can phosphorylate tau – glycogen synthase
kinase 3 (GSK3; tau protein kinase I), cyclin-dependent kinase 5 (CDK5; tau protein kinase II)
and a third kinase, extracellular signal-regulated kinase 2 (ERK2), from the possible 518
member kinase family, as a possible therapeutic approach to treating AD (Hanger et al.,2009
Mazanetz et al.,2007, Brunden et al., 2009). Other kinases that are possible targets to prevent
tau hyperphosphorylation are casein kinase 1 (Hanger et al.,2007), AMP-activated protein
kinase (AMPK) (Greco et al.,2009) and DYRK1A and AKAP-13 (Azorsa et al., 2010). From a
biomarker perspective, t-tau, a generic measure of cortical axon damage associated with AD,
multiple sclerosis (Hernandez et al., 2007, Bartosik-Psujek et al.,2006), stroke and Creuzfeldt-
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Jacob disease, and p-tau are increased by three fold in the CSF of confirmed AD patients (Shaw
et al.,2009). Of the 40 or so phosphorylation sites on tau, pThr181 (phosphothreonine-181),
pSer199, pSer202/pThr205 (AT8, epitopes site), pSer214/pSer212 (AT100, epitopessite),
pThr231/ pSer235 (TG3 site) and pSer396/pSer396 (PHF1 site)–have been associated with tau
hyperphosphorylation and to screen NCEs for potential ‘‘tau kinase’’ inhibitory activity. While
pSer199 and pThr231 (p-tau231) have been evaluated as CSF biomarkers (Buerger et al., 2002;
Engelborghs et al., 2008., table 2), pThr181 (also designated as p-tau181 or P-Tau181P) is the
most widely used CSF biomarker to assess tau hyperphosphorylation (Lewczuk et al., 2002;
Hampel et al., 2004) having similar diagnostic accuracy to p-tau231 (Fagan et al., 2009, table
2). Like Ab42, the diagnostic value of both t-tau and p-tau181 has been questioned in terms of
their specificity as AD biomarkers (Mattsson et al., 2009).
2.3. β-Amyloid-protein
Extracellular senile plaques consisting of beta-amyloid-protein (Aβ) are one of the histopa‐
thological hallmarks of AD (Hyman and Trojanowski., 1997). They are the source of a patho‐
genic protein with 42 amino acids (Aβ1–42) (Selkoe et al., 1993). Several groups have developed
and studied different bioassays specifically designed for Ab1–42 protein (Arai et al., 1997c,
Sunderland et al., 2003). The reduction in CSF Ab1–42 found in AD has been hypothesized to
indirectly reflect the amyloid deposition in senile plaques (SP), resulting in lower CSF levels
in AD. A marked reduction in CSF Ab1–42, however, is also found in CJD, even in cases without
Ab-positive plaques (Kapaki et al., 2001; Otto et al., 2000., table 3).
To date, at least 900 patients with clinical AD and 500 healthy individuals have been enrolled
in independent research studies (Andreasen et al., 2001; Andreasen et al., 1999; Galasko et
al.,  1998;  Sunderland et  al.,  2003.,  table  3).  The most  consistent  finding is  a  marked de‐
crease in Aβ1–42 protein in AD (to approximately 50% of control  levels).  Using Ab1–42
protein alone yielded sensitivities varying from 78% to 100% (table 3) and specificities from
47% to 81% when distinguish AD from elderly controls.  There is a pronounced overlap,
however, between studiesfrom different groups. Based on recent data a cut-off-level of >500
pg=ml has been suggested to discriminate AD best from normal aging (Sjogren et al., 2001a).
One study has documented a significant decrease in CSF Aβ1–42 protein in MCI subjects
compared to controls, but this study had no follow-up measure (Andreasen et al., 1999a).
A second study examined MCI patients who went on to develop AD. However,  in this
sample Aβ1–42 protein levels did not differ significantly from age-matched normal controls
(Maruyama et al., 2001). Blennow et al (2003) found Ab1–42 protein to be an indicator of
early identification of AD in MCI subjects taking potential confounding factors into account
such as age, severity of cognitive decline, time of observation, apolipoprotein E epsilon (e)
4 (APOE e4) carrier status, and gender (Blennow et al., 2003).Studies correlating CSF Aβ1–
42 protein concentrations with cognitive performance in AD have been contradictory. Cross-
sectionally,  the  concentration  of  Aβ1–42  protein  and  cognitive  measures  were  either
inversely correlated (Kanai et al., 1998; Samuels et al., 1999) or no significant correlation was
found  (Andreasenet  al.,  1999b;  Hulstaert  et  al.,  1999;  Okamura  et  al.,  1999).  In  a  rare
longitudinal study, a decrease in CSF Aβ1–42 protein was documented overa three year
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follow-up period (Tapiola et al.,  2000). A highly significant correlation between low CSF
concentrations at  baseline and follow up.  In a separate study,  no correlation was found
between CSF levels and duration or severity of AD (Andreasen et al., 1999b).
2.4. Combination of CSF amyloid and tau phosphorylation
The current limitations of the predictive value of Aβ 42, t-tau and p-tau181 as AD biomarkers
alone, these have been used together to develop a ‘‘CSF AD signature’’, again, with mixed
results (Shaw et al., 2009;Mattsso et al., 2009;Kauwe et al., 2009;Mihaescu et al., 2010;Breno et
al.,2008;De Meyer et al., 2010). While some studies indicate that the combination Aβ 42, t-tau
and p-tau181 biomarker signature in CSF has high predictivity in identifying cases of prodro‐
mal AD in MCI patents (Shaw et al.,2009; Jack et al.,2010; Hansson et al., 2006), there is
considerable intersite variability that can confound biomarker accuracy (Kauwe et al., 2009).
Reduced CSF Aβ 42 and increased CSF p-tau181 concentrations – were used independently of
a clinical diagnosis to stratify patient groups (De Meyer et al., 2010). This AD signature was
found in 90%, 72%, and 36% of patients with AD, mild MCI, and cognitively normal groups
respectively (De Meyer et al., 2010). The cognitively normal group with an AD signature were
enriched in apolipoprotein E4 alleles. Validation of these findings in two further data sets
showed that 64/68 (94% sensitivity) of autopsy-confirmed AD patients were classified with an
AD signature while 57 MCI patients followed for 5 years had a sensitivity of 100% in pro‐
gressing to AD based on their biomarker signature. The presence of a CSF AD signature in
cognitively normal subjects was interpreted by the authors as an indication of AD pathology
being present and detectable far earlier than previously envisioned in disease progression.
2.5. NF proteins
Neurofilaments (NFs) are neuron-specific intermediate filaments and serve as a major cytos‐
keletal component in neurons. In a mature mammalian neuron, NFs are co-assembled from
three subunits, termed NF-H (high), NF-M (medium) and NF-L (low). As NFs are confined to
the nervous system, they might be one of the best markers reflecting neuronal pathogenic
changes seen in some neurological disorders, such as AD. In AD brain, the levels of phos‐
phorylated NF-H/M (pNF-H/M) have been found to be markedly increased (Wang et al.,
2001). Hu et al., (2002) found that, the levels of phosphorylated NF-H/M (pNF-H/M), non-
phosphorylated NF-H/M (npNF-H/M) and NF-L were significantly higher (pNF-H/M,,12–24-
fold; npNF-H/M,,3–4-fold) in neurologically healthy aged people than young individuals. In
AD, the levels of npNF-H/M, and NF-L were similar to vascular dementia (VaD), and higher
than in age-matched controls and the levels of pNF-H/M were significantly higher AD and
ALS than in aged controls and VaD. Based on these findings, it is suggested that the increased
level of total NF, p-NF proteins in CSF could be used as a marker for brain aging and neuro‐
degenerative disorders in general, and the levels of pNF-H/M as a marker to discriminate AD
from normal brain aging and as well as neurological conditions including VaD (Hu et al 2002).
Specific antibodies derived from aberrantly and hyperphosphorylated neuronal intermediate
filament peptides from AD brain as bio markers for early AD detection
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In addition to hyperphosphorylated- tau, recently we have demonstrated the direct evidence
of aberrantly and hyperphosphorylated neuronal intermediated proteins (NF-M/H) as integral
part of NFTs of AD brain using phosphoproteomics (Rudrabhatla et al., 2011., table 5).
Although, NFs have been shown immunohistologically to be part of NFTs, there has been
debate that the identity of NF proteins in NFTs is due to the cross-reactivity of phosphorylated
NF antibodies with phospho-Tau. This study has provided a direct evidence on the identity
of NFs in NFTs by immunochemical and mass spectrometric analysis. For these studies
purified NFTs were used and liquid chromatography/tandem mass spectrometry of NFT
tryptic digests were analysed (table 4-6). The phosphoproteomics of NFTs clearly identified
NF-M phosphopeptides (table 5). Western blotting of purified tangles with SMI31 showed a
150-kDa band corresponding to phospho-NF-M, while RT97 antibodies detected phospho-NF-
H. These observations suggest that expression of some of these genes is elevated in AD in
addition to their phosphorylation. Apart from phosphor Tau, phosphopeptides corresponding
to MAP1B to Ser1270, Ser1274, and Ser1779); and MAP2 (corresponding to Thr350, Ser1702,
and Ser1706) were also identified (table 6). These studies independently demonstrate that NF
and other microtubule proteins are part of NFTs in AD brains (Rudrabhatla et al., 2011). These
promising findings call for further studies on the diagnostic potential of specific antibodies
derived from aberrantly and hyperphosphorylated neuronal intermediate filament (NF-M/H)
peptides from AD brain as bio markers for early AD detection
Phosphopeptide Phosphorylation site
TPPAPKT*PPSSGEPPK Thr181
TPPAPKTPPS*SGEPPK Ser184
TPPAPKTPPSS*GEPPK Ser185
VAVVRT*PPKS*PSSAK Thr231, Ser235
SRT*PSLPT*PPTR Thr212, Thr217
TPSLPT*PPTR Thr217
TDHGAEIVYKS*PVVSGDTSPR Ser396
TDHGAEIVYKSPVVS*GDTSPR Ser400
TDHGAEIVYKS*PVVSGDT*SPR Ser396, Thr403
Table 4. Phosphopeptides and phosphorylation sites identified in NFT Tau
Phosphopeptides Phosphorylation sites
NF-M SPVPKS*PVEEAK Ser685
NF-M KAES*PVKEEAVAEVVTITK Ser736
NF-M VSGSPSS*GFRSQSWSR Ser33
NF-H EPDDAKAKEPS*K Ser942
Table 5. Phosphopeptides and phosphorylation sites identified in NF-M and NF-H
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MAP Sequence Phosphorylation site
MAP1B VLSPLRS*PPLIGSESAYESFLSADDK Ser1274
MAP1B VLSPLRS*PPLIGSESAYESFLSADDK Ser1270
MAP1B VLS*PLRSPPLIGSESAYESFLSADDK Ser1270
MAP2 KIDLS*HVTS*KCGS*LK Ser1702, Ser1706
MAP2 VAIIRT*PPKSPATPK Thr350
Table 6. Phosphopeptides and phosphorylation sites identified in MAP1 and MAP2
2.6. Microtubule-associated proteins and vimentin
Microtubules are polymers of α- and β-tubulin dimers that mediate many functions in neurons,
including organelle transport and cell shape establishment and maintenance as well as axonal
elongation and growthcone steering in neurons. The polymerization, stabilization, and
dynamic properties of microtubules are influenced by interactions with microtubule-associ‐
ated proteins (MAPs). Members of this protein family are classified by size: high molecular
mass proteins (MAP1A, MAP1B, MAP2a, and MAP2b) and intermediate molecular mass
MAPs (MAP2c, MAP2d, and tau) (Gonzalez-Billault,C et al.,2004).
Increasing evidence highlights the critical outcome of MAP modification in cytoskeletal
disorganization associated with the early stages of AD development. A decreased content of
MAP1B and tau associated with cytoskeletal breakdown was found in the brains of AD patients
compared with those of control individuals, suggesting a decreased capacity of microtubule
assembly and stability (Nieto,A et.al 1989). These results are consistent with those of Iqbal et
al. (1986) describing a decreased capacity in the in vitro microtubule assembly from brain
extracts of AD patients. One study has shown an early decrease in MAP2 labeling within
dendrites from AD brain (Adlard, P. A., and Vickers, J. C. 2002). Other studies have demon‐
strated that MAP1B and MAP2 co-localize with NFTs (Kosik et al., 1984; Takahashi, et al.,
1991). Alonso et al. (1997) studied the associations of the Alzheimer-hyperphosphorylated tau
(AD P-tau) with the high molecular weight MAPs (HMW-MAPs) MAP1 and MAP2. The
author found that AD P aggregate with MAP1 and MAP2. The association of AD P-tau to the
MAPs resulted in inhibition of MAP-promoted microtubule assembly. These studies suggest‐
ed that the abnormally phosphorylated tau can sequester both normal tau and HMW-MAPs
and disassemble microtubules.
Vimentin is a 57-kDa intermediate filament (IF) protein commonly found in mesodermally
derived cells. In the healthy adult brain, vimentin is lacking in neurons and generally restricted
to vascular endothelial cells and certain subpopulations of glial cells at specific brain locations.
Eli et al (2009) found that Vimentin was localized to neuronal perikarya and dendrites in AD
brain, with vimentin-immunopositive neurons prevalent in regions exhibiting intra- and
extracellular beta-amyloid1-42 (Aβ42) deposition. Neuronal colocalization of vimentin and
Aβ42 was common in the cerebral cortex, cerebellum and hippocampus (Eli et al., 2009). Our
lab recently discovered that the protein tangles which are a hallmark of the disease involve at
least three different proteins rather than just one (table 4-6). The discovery of these additional
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proteins, neurofilaments, MAP2 and Vimentin, should provide better understanding the
biology and progression of the disease as well as provide additional biomarker at the early
stage of the disease.
2.7. Other CSF biomarkers for AD
As the AD signature approach based on the amyloid and tau causality hypothesis of AD
continues to evolve, other CSF biomarkers are also being assessed. These include CSF cytokines
(Swardfager et al.,2010; Olson etal.,2010 )– specifically TGFβ increases in AD CSF (Swardfager
et al.,2010)– CSF proteomic profiles (Papassotiropoulos et al.,2006), clusterin (Thambisetty et
al.,2010)and IgG antibodies from the adaptive immune system (Reddy et al.,2011) The latter
is a field of intense research, despite the challenges in analyzing proteome profiles, and
involves the study of differences in the CSF proteome in AD, MCI and control subject groups
(Papassotiropoulos et al.,2006;Zhang et al.,2005; Castano et al 2006; Finehout et al.,2007;
Marouf et al.,2009; Choi et al.,2010). One study (Maarouf et al.,2009) reported changes in a
variety of CSF proteins including a-2-macroglobulin, α1-antichymotrypsin,a1-antitrypsin,
complement and heat shock proteins, cathepsinD, enolase and creatine. The ADNI is also
generating CSF proteomic profiles as part of its ‘‘Use of Targeted Multiplex Proteomic
Strategies to Identify Plasma-Based Biomarkers in Alzheimer’s Disease’’ (Miller et al., 2009).
3. Oxidized proteins: Potential candidate biomarkers in AD
Although the pathogenesis of AD is not yet fully known, it is clear that the disease is caused
by a combination of risk factors. Among several hypotheses, oxidative stress is considered to
play a significant role (Butterfield, 2007). Although CSF represents the most suitable biological
fluid to study neurodegenerative diseases since it can reflect the biochemical changes occurring
in brain, its analysis is not always easily feasible for a large scale screening, because the costs
involved are enormous and procedures are invasive, uncomfortable and not without risk. For
a full screening and early diagnosis, biomarkers easily detectable in biological samples, such
as plasma, are needed. Up to now, the search for reliable biomarkers for AD in peripheral
blood is very challenging because of difficulties with the standardization of the methods of
analysis and the low reproducibility of the results. Although a set of plasma markers that
differentiated AD from controls have been shown to be useful in predicting conversion from
MCI to AD (Song., 2009), the study has not been yet verified by other researchers and the
application of these candidate biomarkers have yet to achieve the diagnostic power, sensitivity,
and reproducibility necessary for widespread use in a clinical setting. Oxidized proteins may
represent potential candidate biomarkers for “oxidative stress diseases”, such as AD.
The first report on protein oxidation in CSF samples was from Tohgi et al. (1999) who dem‐
onstrated that 3-nitrotyrosine moderately but significantly increased with advancing age, and
showed a remarkable increase in patients with AD. As the free tyrosine concentration did not
decrease, the increase in 3-nitrotyrosine with age or associated with AD did not appear to be
directly related to an increase in free-nitrated tyrosines. Rather, the increased 3-nitrotyrosine
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was likely due to an increase in nitrated tyrosines in proteins or increased degradation of 3-
nitrotyrosin containing proteins, which are highly vulnerable to degradation.The most reliable
CSF markers in AD are Aβ42 and tau. Low CSF Aβ 42 is associated with amyloid pathology
in the brain and high Tau is linked with neurofibrillary pathology (Frey etal. 2005). Most
subjects with decreased CSF Aβ42 and high tau develop AD during the follow-up (Herukka
et al., 2007). Therefore, these CSF markers may reflect brain pathology and identify preclinical
AD. Interestingly, the levels of CSF Aβ42 showed a tendency to correlate positively with serum
oxidative markers in the whole study population and with plasma nitrotyrosines in AD
patients. Moreover, a negative correlation between CSF tau and serum nitrotyrosine levels was
evidenced in controls (Korolainen et al., 2009). The correlation between CSF AD markers and
blood oxidative markers may suggest that oxidative metabolism is changed in AD. This
hypothesis is further supported by the finding of decreased CSF protein carbonylation in
APOE ε4 carriers, which is considered an important risk factor for developing AD (Raber et
al., 2004) and correlates with redox proteomics studies that identified metabolic proteins as
oxidatively modified and dysfunctional (Choi et al., 2004).
Subsequently, Ahmed et al. (2005) measured in CSF the levels of protein glycation, oxidation
and nitration. The authors found that the concentrations of 3-nitrotyrosine,Nε-carboxymethyl-
lysine,3-deoxyglucosone-derived hydroimidazolone and N-formylkynurenine (as markers of
protein glycation) were increased in subjects with AD. The Mini-Mental State Examination
(MMSE) score correlated negatively with 3-nitrotyrosine residue concentration. These findings
indicated that protein glycation, oxidation and nitration were increased in the CSF of subjects
with AD. A combination of nitration and glycation adduct estimates of CSF may conceivably
provide an indicator for the diagnosis of AD. Increased levels of protein aggregates in the form
of fibrils together with increased lipid peroxidation have been shown, both in AD andMCI
brain (Butterfield et al., 2010).
Advanced oxidation end products (AOEs,) during AD, colocalize with neurofibrillary tangles,
senile plaques, microglia, and astrocytes and have been also measured in plasma. Advanced
oxidation protein products (AOPPs), a relatively novel marker of oxidative damage, are
considered as reliable markers to estimate the degree of oxidant-mediated protein damage. A
significant increase in protein carbonyls in hippocampus (HP) and inferior parietal lobule (IPL)
of AD subjects compared with age-matched controls was observed. Dityrosine and 3-NT total
levels were reported to be elevated in the hippocampus, IPL, and neocortical regions of AD
brain. Alterations in brain phospholipids pattern, a more specific assessment of lipid peroxi‐
dation, have been reported for AD brain (Lovell et al., 1995; Nitsch etal.,1992; Prasad etal.,
1998). The levels of phosphatidylinositol (PI) and phosphatidylethanolamine (PE), rich in
easily oxidizable PUFA, are decreased in AD brain. The levels of F(2)-isoprostanes [F(2)-IsoP],
F(4)-neuroprostane[F(4)-NP], and isoprostane 8,12-iso-iPF2(α)-VI were also found to be
increased in AD brain compared to controls (Montine et al.,2002; Mark et al,1999). An increase
in free HNE has been demonstrated in amygdala, hippocampus, and parahippocampal gyrus
of the AD brain compared with age matched controls (Markesbery.,1998). Several proteins
mainly involved in energy metabolism pathways, pH regulation, and mitochondrial func‐
tionsamong others, were found carbonylated, HNE-bound or nitrated in AD brain (Sultana,
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2006). Newman et al (2007) also reported that a number of proteins modified by glutathiony‐
lation in AD IPL.
Previous studies on CSF nitrite and nitrate levels in patients with AD have provided contra‐
dictory results, with some showing decreased nitrate levels (Kuiper.,1994), others showing
unaltered nitrite/nitrate levels (Ikeda.,1995), and still others increased nitrate levels (Tohgi.,
1998). However, another study from the same group showed that nitrite/nitrate levels in AD
were stage-dependent, being elevated only in the early phase of AD and decreasing to control
levels with disease progression (Tohgi., 1998). This finding was interpreted to reflect progres‐
sive reduction of neurons. In contrast, free 3-nitrotyrosine levels increased significantly in
parallel with the severity of AD, suggesting that protein degradation increases with disease
progression, resulting in increased release of free 3-nitrotyrosine from tyrosine residues that
have been nitrated. 3-nitrotyrosine and the 3-nitrotyrosine/tyrosine ratios in the CSF, both of
which are believed to reflect degradation of nitrated tyrosine-containing proteins, increased
significantly with age and were remarkably higher in patients with AD than in controls.
A study by Choi et al.  (2002) identified uniquely oxidized proteins in AD plasma. These
authors  applied two-dimensional  gel  electrophoresis  (2DE)  coupled with  immunological
staining  of  protein  carbonyl  and  the  oxidized  proteins  observed  in  the  plasma of  both
AD subjects  and non-AD controls  were  determined.  However,  the  level  of  oxidation of
these  protein  spots  was  markedly  higher  in  the  AD samples.  They also  found that  the
increased oxidation was not a generalized phenomenon. In the total protein stain profile,
more than 300 spots were detected, but less than 20 spots were positive by immunostain‐
ing with anti-DNP antibody. Furthermore, of the seven proteins that were most intensive‐
ly oxidized, their relative levels of oxidation differed. These studies found that fibrinogen
gamma  chain  precursor  and  alpha  1  antitrypsinprecursor  showed  increased  levels  of
carbonyl groups in AD comparedwith controls (Stief et al.,  1989).
4. Identification of a new plasma biomarker of AD using metabolomics
technology
Current metabolomics research involves the identification and quantification of hundreds to
thousands of small-molecular-mass metabolites (<1,500 Daltons) in cells, tissues, or biological
fluids. The aims of such studies are typically to understand new diagnosis biomarkers, to
understand the mechanism of action of therapeutic compounds, and to uncover the pharma‐
codynamics and kinetic markers of drugs in patients and in preclinical in vivo and in vitro
models (Wilcoxen et al., 2010). Lipidomics is one of the metabolomics approaches used to
analyze lipid species in biological systems (Hu et al., 2009; Han et al., 2005; Han and Gross,
2003). Investigating lipid biochemistry using a lipidomics approach will not only provide
insights into the specific roles of lipid molecular species in healthy individuals and patients
but will also assist in identifying potential biomarkers for establishing preventive or thera‐
peutic approaches for human health (Hu et al., 2009,Wenk.,2005; Rosenson.,2010 ). Lipidomics
has recently captured attention, owing to the well-recognized roles of lipids in numerous
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human diseases such as diabetes, obesity, atherosclerosis, and AD (Wenk et al., 2005; Watson.,
2006; Steinberg,. 2005; Sato et al., 2010). In support of the hypothesis that lipid dysfunction
plays an important role in AD pathogenesis, previous studies with post-mortem brain tissue
samples have demonstrated altered lipidomes at the different stage of AD pathogenesis. For
example, multiple classes of sphingolipids are altered not only at the late stage of the disease
but also at the earliest clinically recognizable stage of AD. All major classes of phospholipids
are ubiquitously decreased at the late stage of AD. Among these, the levels of plasmalogen (a
major component in nerve tissue membranes counting for up to 85% of ethanolamine glycer‐
ophospholipid, or ∼30% of total phospholipids of these membranes) are gradually reduced as
progress of AD severity (Han et al., 2011). Sato et al (2011) established a lipidomics method for
comprehensive phospholipids evaluation that identified 31 phospholipids as AD biomarker
candidates in human plasma using LC/MS (Satoet al., 2010). Moreover, additional studies have
suggested that AD associates with other lipid metabolism pathways and lipid carrier proteins
such as apoE (Bertram et al., 2008; Corder et al., 1993; Farrer et al., 1997; Strittmatter et al., 1993).
A very recent study by Sato et al (2011) were able to find a biomarker desmosterol that changes
in AD compared with plasma from healthy elderly controls. They have shown that desmosterol
plasma level and the desmosterol/cholesterol ratio in the same patients was significantly
decreased. This study is the first report that plasma desmosterol levels are decreased in AD
and MCI. And future studies are needed to confirm whether desmosterol could become an
attractive plasma AD biomarker that could perhaps also be utilized for diagnosis and as well
as for monitoring noninvasively the effect of future AD drugs on disease progression.
5. MicroRNAs as biomarkers for AD
MicroRNAs (miRNAs) are a class of small, endogenous, noncoding RNA molecules that serve
as posttranscriptional regulators of gene expression (Lee etal.,1993;Giannakakis etal.,2007).
miRNAs are acquiring important and determinant roles in the regulation of brain gene
transcription in health and disease: the fact that approximately 80% of the human brain genome
is transcribed into RNA, but only about 2% of the genome is transcribed into protein, under‐
scores the potential of various levels of RNA signaling and epigenetic mechanisms to contrib‐
ute to physiological gene control (Makeyevetal., 2008). In the last few years, miRNAs have
been emerging as important regulators of various aspects of neuronal development and
dysfunction (Gao.,2007; Lukiw.,2007). The role of miRNAs in neurodegenerative diseases has
been investigated using miRNA microarray profiling in brain tissue samples derived from
patients and controls. Using miRNA expression profiling in cortex samples from a well-
characterized clinicopathological series of elderly controls, MCI subjects and AD patients,
Wang et al (2008) identified miR-107 to be specifically decreased early in the course of AD.
Computational analyses predicted BACE1 mRNA as a target of miR-107 and correlative
mRNA expression studies confirmed its role in regulating BACE1 expression. An independent
miRNA profiling study by Hebert et al (2008) confirmed the importance of BACE1 regulation
by miRNAs. The presence of a modulation of miRNA in regions of brain targeted by AD
neuropathology was further demonstrated (Lukiw et al., 2008; Lukiw., 2009), thus suggesting
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a specific involvement of miRNAs in pathogenetic signaling pathways associated with the AD
process. Recent findings suggest that neuronal miRNA deregulation in response to an insult
by Aβ may be an important factor contributing to the cascade of events leading to AD
(Schonrock, et al., 2010). Of note, the upregulation of peripheral miRNAs in AD could
contribute to the diminished plasma proteins reported to be predictive biomarkers for AD
(Ray Set al., 2007). In addition, it has recently been reported that miRNAs can be detected in
CSF: an altered regulation of miRNA expression in AD brains was paralleled by a modulation
of miRNA levels in the CSF (Cogswell et al., 2008). These studies provide an initial hope that
miRNAs could represent accessible biomarkers to support clinical diagnosis in the near future.
6. Timing and other influencing factors of biomarker use
Disease modifying drugs are likely to be most effective in the earlier stages of AD, before
neurodegeneration is too severe and widespread, so trials for this type of drug will need to
include AD cases in the earlier stages of the disease. Validated biomarkers that could enable
accurate identification of AD pathology at an early stage would be of great use (Hampel et
al., 2011). Alternatively, baseline biomarker measurements can be used for enrichment and
stratification in proof-of concept studies, as well as for supporting go/no-go decision making
of phase III trials. Biomarkers should be used in all stages of drug development including
phase I, phase II and phase III. They can be used to enhance inclusion and exclusion criteria,
for stratification. Biomarkers can also be used as outcome markers to detect treatment effects.
Particularly, if biomarkers are intended to be used as surrogate endpoints in pivotal studies,
they must have been qualified to be a substitute for a clinical standard of truth and as such
reasonably predict a clinical meaningful outcome. Finally, biomarkers can be used to identify
adverse effects. Nevertheless there are several pitfalls to be faced in the interpretation of
biomarker data in AD drug development, such as the fact that biomarkers may be non-
specific to AD, it may not be feasible to measure them in the appropriate system (i.e. the
central nervous system) and the risk of over-interpreting biomarker data in phase II trials
if  statistical  significance  levels  are  not  adjusted  for  multiple  comparisons  (Aisen,  2009).
Failure  to  consider  these  issues  could  contribute  to  false  conclusions  and  costly  errors
(Hampel et al., 2011; Hampel et al., 2004)
7. Conclusion and future directions
Several promising drug candidates with disease-modifying effect, such as Aβ  immunother‐
apy, secretase modulators, and tau aggregation inhibitors, have now reached the stage of
being  tested  in  clinical  trials.  The  promise  of  disease-modifying  therapy  has  created  a
need for biomarkers to enable the clinical  identification of the disease at  an early stage.
Early  diagnosis  will  be  of  great  importance  since  disease-modifying drugs  are  likely  to
be  most  effective  in  the  earlier  stages  of  the  disease,  before  neurodegeneration  is  too
severe and widespread. A large number of studies have demonstrated that tests based on
Candidate Bio-Markers of Alzheimer’s Disease
http://dx.doi.org/10.5772/55069
207
CSF  t-tau  protein,  p-tau  and  CSF  beta-amyloid1–42  have  reasonable  specificity  and
sensitivity when differentiating AD from normal aging. A smaller number of studies show
similar accuracy when distinguishing AD from major depression. These tests may also be
useful in detecting MCI patients who go on to develop AD.
Unfortunately, the value of these biomarkers to clinicians is limited, because they are not
specific enough to accurately separate AD from other common forms of dementia, such as VaD
and LBD. Sometimes the combination of both CSF t-tau protein and CSF Aβ1–42 markers does
not markedly improve on their individual sensitivity. CSF p-tau, based on different phos‐
phorylation epitopes of tau protein, has now been examined in a number of independent
studies. Initial results are extremely promising, showing that different p-tau protein epitopes
may substantially contribute to improved diagnostic accuracy of AD in comparison with
healthy aged controls, elderly depressed patients and those with other types of dementia.
Compared with CSF t-tau protein and CSF Ab1–42 markers, CSF p-tau is more specific and
less influenced by age or degree of cognitive decline (Hampel et al., 2004). This has an
important implication for the value of CSF p-tau to clinicians. If the marker becomes abnormal
very early in the course of disease relatively independent from the degree of cognitive decline
than the marker may be ideal as a diagnostic test. If, however, the marker is closely linked to
current or future cognitive decline, then it may be better suited as a prognostic tool. Studies of
all possible biomarkers to date in AD, suggest p-tau comes the closest to the ideal diagnostic
marker. However, different epitopes of p-tau may have different strengths and weaknesses.
CSF p-tau231 may be most useful in distinguishing AD from frontotemporal dementia (FTD).
CSF p-tau181 may improve separation between AD and LBD. In addition, CSF p-tau231 may
be the most useful prognostic marker candidates that predicts cognitive decline to AD in MCI
subjects.Further studies are needed to decide whether detection of multiple phosphoepitopes
may allow a distinct representation of AD related pathology at different stages of the disease
(Augustinack et al., 2002).
NFTs contain aberrantly hyperphosphorylated Tau as paired helical filaments. Although NFs
have been shown immunohistologically to be part of NFTs, there has been debate that the
identity of NF proteins in NFTs is due to the cross-reactivity of phosphorylated NF antibodies
with phospho-Tau. Our laboratory recently reported (Rudrabhatla et al., 2010, 2011) the direct
evidence of NFs in NFTs. Moreover, neuronal death and degeneration may release fragments
of these proteins into body fluids at sufficient levels to be easily detected by specific antibodies
at early, preclinical stages of AD. A battery of antibodies to NF-specific phosphoepitopes and
Tau in NFTs may offer a unique approach to the design of effective early biomarkers.
The rapidly developing fields of large-scale and massive-scale genomics, proteomics, and
metabolomics are now joining functional neuroimaging, structural neuroimaging, and
neuropsychometric contenders in the race to establish useful biomarkers of AD and other
dementing illnesses. Redox proteomics studies have provided insights into the role of
oxidative stress in AD pathology. Posttranslational modifications of brain proteins, induced
by oxidative damage, lead to impairment and dysfunction of several cellular functions thus
providing clues about important molecular basis of neurodegeneration associated to AD. In
addition, these studies have identified specific therapeutic targets in this disorder. In recent
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years, growing studies have been focused to establish a direct link between tissue specific
oxidation and systemic oxidative damage (Blennow et al., 2010; Korolainen et al 2010; Ahmed
et al., 2005; Aksenov et al., 2001). Correlations between total levels of oxidation markers in the
brain and in the periphery have been shown. Although some of the reported results in AD are
controversial, most of them support the presence of peripheral oxidative damage and of a
characteristic panel of systemic oxidation that correlates with the occurrence of the disease.
Studies investigating oxidative stress outside of the CNS, particularly in blood, while prove
the occurrence of oxidative reactions, are not fully elucidating the complex cascade of events.
Thus, one hypothesis is that oxidative stress first develops in the periphery as a result of
different causes, and then it will contribute to perturb neuronal homeostasis, either by
increasing the production of ROS or by depleting antioxidant defense, which will eventually
lead to oxidative damage of the brain and neurodegeneration. The development of new plasma
biomarkers could facilitate early detection, risk assessment and therapeutic monitoring in AD.
On the other hand, it is also possible to imagine that oxidative stress starts in the CNS where
several different metabolic end-products are formed and released into the blood stream. In
this context, an important issue is to perform further studies in order to investigate the timing
of appearance of oxidative damage signatures at systemic level during the onset of AD early
stages and the progression to late stages.
Recently, important steps have been accomplished but there is still a lot of work to be directed
towards the discovery, testing and validation of a panel of novel and old assays that could
serve all the requirements for ideal biomarkers. However, the emerging trend which results
from the collection of multiple data from different source is the wide variability among
different studies that led to contrasting results. Thus, there is an urgent need to standardize
protocols for replicate experiments on large population, which may allow to better under‐
standing the effect of systemic oxidative damage in the pathogenesis and progression of AD.
Indeed, this is also evident by the lack of redox proteomics and microRNA studies applied to
biological fluids. This approach has the power to search for specific microRNA and protein
oxidative modification thus allowing the identification of altered miroRNA and protein in
complex matrices such as body fluids, which may discriminate AD vs healthy condition.
There are several different reasons to support the development of more sensitive method to
detect a biochemical marker in AD: to increase diagnostic accuracy; to identify MCI subjects
who will progress to clinical AD; to monitor pharmacological and biological effects of drugs.
There is an urgent need to add further peripheral markers of oxidative stress as useful
diagnostic biomarker. There is clearly a growing interest among clinicians and basic scientists
to tap on each other’s expertise in the area of ageing neurobiology research. Such collaborations
between geriatricians, neuroimaging specialists, neuropsychiatrists as well as molecular and
cellular neurobiologists are being fostered. Further research is necessary to improve especially
the early/differential biochemical diagnosis of AD. Some considerations need to be taken into
account when designing future studies. These should include high numbers of relevant AD of
different origin, a combination of biomarkers and other risk factors, long-term follow- up of
patients and if possible neuropathological verification of the diagnosis. Standardization of
methods seems critical to reducing inconsistency and increasing reliability. It is necessary to
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implement common protocols for sample preparation, experimental design and generation of
proteomics data. Thus, global initiatives of standardization are of critical importance and large
multicenter studies are needed to further define the added diagnostic value when multiple
biomarker modalities are combined.
The essential goal in biomarker discovery studies is the identification of preclinical marker,
which facilitates disease diagnosis at earlystages, is hoped that markers of prognosis will
enable clinicians to monitor whether new candidate treatments of AD are working, effectively
and inexpensively and assesses the response to treatments by the time that disease-modifying
treatments become available in clinical practice.
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